Trending at Lumira Ventures

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy – Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, …

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., March 02, 2021 …

G1 Therapeutics Reports Q3 2019 Financials

Jennifer Schram G1 Therapeutics, Portfolio News

RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2019. Review the full filling here. “Based on written feedback from the FDA following our pre-NDA meeting …

Trial Results Show Trilaciclib Decreases Myelosuppression in Extensive-Stage Small Cell Lung Cancer (SCLC) Patients

Jennifer Schram G1 Therapeutics, Portfolio News

This global, randomized, double-blind, placebo-controlled, multicenter, Phase 2 study (NCT03041311) assessed the potential of trilaciclib to reduce the incidence and consequences of chemotherapy-induced myelosuppression in patients with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC) treated with etoposide, carboplatin and atezolizumab …

G1 Therapeutics presents data from Phase 2 mTNBC trial for trilaciclib at ESMO19

Jennifer Schram G1 Therapeutics, Portfolio News

RESEARCH TRIANGLE PARK, N.C. and BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic …

FDA Grants G1 Therapeutics Breakthrough Therapy Designation & Provides Q2 2019 Financial Update

Jennifer Schram G1 Therapeutics, Portfolio News

Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …

Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy

Jennifer Schram G1 Therapeutics, Portfolio News

– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …